Cytori Therapeutics (CYTX) Shares Up 16.1%

Cytori Therapeutics Inc (NASDAQ:CYTX) shot up 16.1% during mid-day trading on Wednesday . The company traded as high as $0.37 and last traded at $0.36. 1,820,975 shares changed hands during mid-day trading, a decline of 23% from the average session volume of 2,367,844 shares. The stock had previously closed at $0.31.

A number of research firms recently issued reports on CYTX. B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Maxim Group set a $5.00 price objective on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Finally, ValuEngine upgraded shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

The firm has a market cap of $12.60, a P/E ratio of -0.40 and a beta of 3.56.

In other Cytori Therapeutics news, major shareholder Ag Postfinance sold 286,982 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total transaction of $88,964.42. Following the completion of the sale, the insider now directly owns 5,118,627 shares in the company, valued at $1,586,774.37. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 695,767 shares of company stock valued at $231,951. 1.90% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. grew its stake in Cytori Therapeutics by 134.0% during the fourth quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock worth $644,000 after buying an additional 1,223,046 shares during the period. Sabby Management LLC lifted its position in shares of Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 355,504 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Cytori Therapeutics by 81.9% during the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after purchasing an additional 275,653 shares in the last quarter. Institutional investors own 10.82% of the company’s stock.

WARNING: “Cytori Therapeutics (CYTX) Shares Up 16.1%” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2018/02/14/cytori-therapeutics-cytx-shares-up-16-1.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit